Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biological Signal Processing Ltd.
FDA approval granted for new ECG technology
April 26th, 2005
Biological Signal Processing Ltd. (BSP) has received U.S. Food & Drug Administration (FDA) approval for the marketing and sale of its HyperQ System. BSP, developer of high-frequency ECG (HF ECG), has developed ECG technology with breakthrough diagnostic value for detecting and monitoring ischemic heart diseases (IHD) - the leading cause of death in the developed world. BSP's HyperQ System is a unique PC-based stress ECG device, that records, analyses and displays both conventional stress ECG and HF ECG for detection of myocardial ischemia. The system uses BSP's proprietary signal acquisition and signal processing technology and...
Source: Cardiovascular Business Week (2005-04-26)
|
